世界のペプチドベース感染症治療薬市場規模・現状・予測2021-2027

【英語タイトル】Global Peptide Based Infection Therapeutics Market Size, Status and Forecast 2021-2027

QYResearchが出版した調査資料(QY21APR4500)・商品コード:QY21APR4500
・発行会社(調査会社):QYResearch
・発行日:2021年4月(※2024年版があります。お問い合わせください)
・ページ数:90
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査資料では、ペプチドベース感染症治療薬の世界市場(2016年~2027年)を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模(テラプレビル、ソフォスブビル、その他)、用途別市場規模(病院薬局、ドラッグストア、オンライン薬局)、主要地域別市場規模(北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、企業情報などをまとめております。
・市場概要
・ペプチドベース感染症治療薬の市場動向
・企業の競争状況、市場シェア
・ペプチドベース感染症治療薬の種類別市場規模(テラプレビル、ソフォスブビル、その他)
・ペプチドベース感染症治療薬の用途別市場規模(病院薬局、ドラッグストア、オンライン薬局)
・ペプチドベース感染症治療薬の北米市場規模2016-2027(アメリカ、カナダ)
・ペプチドベース感染症治療薬の欧州市場規模2016-2027(ドイツ、フランス、イギリス等)
・ペプチドベース感染症治療薬のアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等)
・ペプチドベース感染症治療薬の中南米市場規模2016-2027(メキシコ、ブラジル)
・ペプチドベース感染症治療薬の中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等)
・主要企業情報(Gilead Sciences、Johnson & Johnson (Janssen)、Vertex Pharmaceuticals、Mitsubishi Tanabe Pharma、Medivir)
・結論
【レポートの概要】

Peptide therapeutics are stable, safe, tolerable, possess selective nature, and effective.
Hospital pharmacies segment enjoys the highest market share by revenue thereby dominating the global market.

Market Analysis and Insights: Global Peptide Based Infection Therapeutics Market
The global Peptide Based Infection Therapeutics market size is projected to reach US$ 33050 million by 2026, from US$ 22880 million in 2019, at a CAGR of 5.3% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Peptide Based Infection Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Peptide Based Infection Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Peptide Based Infection Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Peptide Based Infection Therapeutics market.

Global Peptide Based Infection Therapeutics Scope and Market Size
Peptide Based Infection Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Peptide Based Infection Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Telaprevir
Sofosbuvir
Others

Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Gilead Sciences
Johnson & Johnson (Janssen)
Vertex Pharmaceuticals
Mitsubishi Tanabe Pharma
Medivir

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Peptide Based Infection Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Telaprevir
1.2.3 Sofosbuvir
1.2.4 Others
1.3 Market by Application
1.3.1 Global Peptide Based Infection Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Peptide Based Infection Therapeutics Market Perspective (2016-2027)
2.2 Peptide Based Infection Therapeutics Growth Trends by Regions
2.2.1 Peptide Based Infection Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Peptide Based Infection Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Peptide Based Infection Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Peptide Based Infection Therapeutics Industry Dynamic
2.3.1 Peptide Based Infection Therapeutics Market Trends
2.3.2 Peptide Based Infection Therapeutics Market Drivers
2.3.3 Peptide Based Infection Therapeutics Market Challenges
2.3.4 Peptide Based Infection Therapeutics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Peptide Based Infection Therapeutics Players by Revenue
3.1.1 Global Top Peptide Based Infection Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Peptide Based Infection Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Peptide Based Infection Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Peptide Based Infection Therapeutics Revenue
3.4 Global Peptide Based Infection Therapeutics Market Concentration Ratio
3.4.1 Global Peptide Based Infection Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Peptide Based Infection Therapeutics Revenue in 2020
3.5 Peptide Based Infection Therapeutics Key Players Head office and Area Served
3.6 Key Players Peptide Based Infection Therapeutics Product Solution and Service
3.7 Date of Enter into Peptide Based Infection Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Peptide Based Infection Therapeutics Breakdown Data by Type
4.1 Global Peptide Based Infection Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Peptide Based Infection Therapeutics Forecasted Market Size by Type (2022-2027)

5 Peptide Based Infection Therapeutics Breakdown Data by Application
5.1 Global Peptide Based Infection Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Peptide Based Infection Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Peptide Based Infection Therapeutics Market Size (2016-2027)
6.2 North America Peptide Based Infection Therapeutics Market Size by Type
6.2.1 North America Peptide Based Infection Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Peptide Based Infection Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Peptide Based Infection Therapeutics Market Size by Type (2016-2027)
6.3 North America Peptide Based Infection Therapeutics Market Size by Application
6.3.1 North America Peptide Based Infection Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Peptide Based Infection Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Peptide Based Infection Therapeutics Market Size by Application (2016-2027)
6.4 North America Peptide Based Infection Therapeutics Market Size by Country
6.4.1 North America Peptide Based Infection Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Peptide Based Infection Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Peptide Based Infection Therapeutics Market Size (2016-2027)
7.2 Europe Peptide Based Infection Therapeutics Market Size by Type
7.2.1 Europe Peptide Based Infection Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Peptide Based Infection Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Peptide Based Infection Therapeutics Market Size by Type (2016-2027)
7.3 Europe Peptide Based Infection Therapeutics Market Size by Application
7.3.1 Europe Peptide Based Infection Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Peptide Based Infection Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Peptide Based Infection Therapeutics Market Size by Application (2016-2027)
7.4 Europe Peptide Based Infection Therapeutics Market Size by Country
7.4.1 Europe Peptide Based Infection Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Peptide Based Infection Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Peptide Based Infection Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Peptide Based Infection Therapeutics Market Size by Type
8.2.1 Asia-Pacific Peptide Based Infection Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Peptide Based Infection Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Peptide Based Infection Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Peptide Based Infection Therapeutics Market Size by Application
8.3.1 Asia-Pacific Peptide Based Infection Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Peptide Based Infection Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Peptide Based Infection Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Peptide Based Infection Therapeutics Market Size by Region
8.4.1 Asia-Pacific Peptide Based Infection Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Peptide Based Infection Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Peptide Based Infection Therapeutics Market Size (2016-2027)
9.2 Latin America Peptide Based Infection Therapeutics Market Size by Type
9.2.1 Latin America Peptide Based Infection Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Peptide Based Infection Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Peptide Based Infection Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Peptide Based Infection Therapeutics Market Size by Application
9.3.1 Latin America Peptide Based Infection Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Peptide Based Infection Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Peptide Based Infection Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Peptide Based Infection Therapeutics Market Size by Country
9.4.1 Latin America Peptide Based Infection Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Peptide Based Infection Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Peptide Based Infection Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Peptide Based Infection Therapeutics Market Size by Type
10.2.1 Middle East & Africa Peptide Based Infection Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Peptide Based Infection Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Peptide Based Infection Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Peptide Based Infection Therapeutics Market Size by Application
10.3.1 Middle East & Africa Peptide Based Infection Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Peptide Based Infection Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Peptide Based Infection Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Peptide Based Infection Therapeutics Market Size by Country
10.4.1 Middle East & Africa Peptide Based Infection Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Peptide Based Infection Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Gilead Sciences
11.1.1 Gilead Sciences Company Details
11.1.2 Gilead Sciences Business Overview
11.1.3 Gilead Sciences Peptide Based Infection Therapeutics Introduction
11.1.4 Gilead Sciences Revenue in Peptide Based Infection Therapeutics Business (2016-2021)
11.1.5 Gilead Sciences Recent Development
11.2 Johnson & Johnson (Janssen)
11.2.1 Johnson & Johnson (Janssen) Company Details
11.2.2 Johnson & Johnson (Janssen) Business Overview
11.2.3 Johnson & Johnson (Janssen) Peptide Based Infection Therapeutics Introduction
11.2.4 Johnson & Johnson (Janssen) Revenue in Peptide Based Infection Therapeutics Business (2016-2021)
11.2.5 Johnson & Johnson (Janssen) Recent Development
11.3 Vertex Pharmaceuticals
11.3.1 Vertex Pharmaceuticals Company Details
11.3.2 Vertex Pharmaceuticals Business Overview
11.3.3 Vertex Pharmaceuticals Peptide Based Infection Therapeutics Introduction
11.3.4 Vertex Pharmaceuticals Revenue in Peptide Based Infection Therapeutics Business (2016-2021)
11.3.5 Vertex Pharmaceuticals Recent Development
11.4 Mitsubishi Tanabe Pharma
11.4.1 Mitsubishi Tanabe Pharma Company Details
11.4.2 Mitsubishi Tanabe Pharma Business Overview
11.4.3 Mitsubishi Tanabe Pharma Peptide Based Infection Therapeutics Introduction
11.4.4 Mitsubishi Tanabe Pharma Revenue in Peptide Based Infection Therapeutics Business (2016-2021)
11.4.5 Mitsubishi Tanabe Pharma Recent Development
11.5 Medivir
11.5.1 Medivir Company Details
11.5.2 Medivir Business Overview
11.5.3 Medivir Peptide Based Infection Therapeutics Introduction
11.5.4 Medivir Revenue in Peptide Based Infection Therapeutics Business (2016-2021)
11.5.5 Medivir Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Peptide Based Infection Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Telaprevir
Table 3. Key Players of Sofosbuvir
Table 4. Key Players of Others
Table 5. Global Peptide Based Infection Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Peptide Based Infection Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Peptide Based Infection Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Peptide Based Infection Therapeutics Market Share by Regions (2016-2021)
Table 9. Global Peptide Based Infection Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Peptide Based Infection Therapeutics Market Share by Regions (2022-2027)
Table 11. Peptide Based Infection Therapeutics Market Trends
Table 12. Peptide Based Infection Therapeutics Market Drivers
Table 13. Peptide Based Infection Therapeutics Market Challenges
Table 14. Peptide Based Infection Therapeutics Market Restraints
Table 15. Global Peptide Based Infection Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Peptide Based Infection Therapeutics Market Share by Players (2016-2021)
Table 17. Global Top Peptide Based Infection Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Peptide Based Infection Therapeutics as of 2020)
Table 18. Ranking of Global Top Peptide Based Infection Therapeutics Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Peptide Based Infection Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Peptide Based Infection Therapeutics Product Solution and Service
Table 22. Date of Enter into Peptide Based Infection Therapeutics Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Peptide Based Infection Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Peptide Based Infection Therapeutics Revenue Market Share by Type (2016-2021)
Table 26. Global Peptide Based Infection Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Peptide Based Infection Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Peptide Based Infection Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Peptide Based Infection Therapeutics Revenue Market Share by Application (2016-2021)
Table 30. Global Peptide Based Infection Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Peptide Based Infection Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Peptide Based Infection Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Peptide Based Infection Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Peptide Based Infection Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Peptide Based Infection Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Peptide Based Infection Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Peptide Based Infection Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Peptide Based Infection Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Peptide Based Infection Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Peptide Based Infection Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Peptide Based Infection Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Peptide Based Infection Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Peptide Based Infection Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Peptide Based Infection Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Peptide Based Infection Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Peptide Based Infection Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Peptide Based Infection Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Peptide Based Infection Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Peptide Based Infection Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Peptide Based Infection Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Peptide Based Infection Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Peptide Based Infection Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Peptide Based Infection Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Peptide Based Infection Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Peptide Based Infection Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Peptide Based Infection Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Peptide Based Infection Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Peptide Based Infection Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Peptide Based Infection Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Peptide Based Infection Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Peptide Based Infection Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 62. Gilead Sciences Company Details
Table 63. Gilead Sciences Business Overview
Table 64. Gilead Sciences Peptide Based Infection Therapeutics Product
Table 65. Gilead Sciences Revenue in Peptide Based Infection Therapeutics Business (2016-2021) & (US$ Million)
Table 66. Gilead Sciences Recent Development
Table 67. Johnson & Johnson (Janssen) Company Details
Table 68. Johnson & Johnson (Janssen) Business Overview
Table 69. Johnson & Johnson (Janssen) Peptide Based Infection Therapeutics Product
Table 70. Johnson & Johnson (Janssen) Revenue in Peptide Based Infection Therapeutics Business (2016-2021) & (US$ Million)
Table 71. Johnson & Johnson (Janssen) Recent Development
Table 72. Vertex Pharmaceuticals Company Details
Table 73. Vertex Pharmaceuticals Business Overview
Table 74. Vertex Pharmaceuticals Peptide Based Infection Therapeutics Product
Table 75. Vertex Pharmaceuticals Revenue in Peptide Based Infection Therapeutics Business (2016-2021) & (US$ Million)
Table 76. Vertex Pharmaceuticals Recent Development
Table 77. Mitsubishi Tanabe Pharma Company Details
Table 78. Mitsubishi Tanabe Pharma Business Overview
Table 79. Mitsubishi Tanabe Pharma Peptide Based Infection Therapeutics Product
Table 80. Mitsubishi Tanabe Pharma Revenue in Peptide Based Infection Therapeutics Business (2016-2021) & (US$ Million)
Table 81. Mitsubishi Tanabe Pharma Recent Development
Table 82. Medivir Company Details
Table 83. Medivir Business Overview
Table 84. Medivir Peptide Based Infection Therapeutics Product
Table 85. Medivir Revenue in Peptide Based Infection Therapeutics Business (2016-2021) & (US$ Million)
Table 86. Medivir Recent Development
Table 87. Research Programs/Design for This Report
Table 88. Key Data Information from Secondary Sources
Table 89. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Peptide Based Infection Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. Telaprevir Features
Figure 3. Sofosbuvir Features
Figure 4. Others Features
Figure 5. Global Peptide Based Infection Therapeutics Market Share by Application: 2020 VS 2027
Figure 6. Hospital Pharmacies Case Studies
Figure 7. Retail Pharmacies Case Studies
Figure 8. Online Pharmacies Case Studies
Figure 9. Peptide Based Infection Therapeutics Report Years Considered
Figure 10. Global Peptide Based Infection Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Peptide Based Infection Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Peptide Based Infection Therapeutics Market Share by Regions: 2020 VS 2027
Figure 13. Global Peptide Based Infection Therapeutics Market Share by Regions (2022-2027)
Figure 14. Global Peptide Based Infection Therapeutics Market Share by Players in 2020
Figure 15. Global Top Peptide Based Infection Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Peptide Based Infection Therapeutics as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Peptide Based Infection Therapeutics Revenue in 2020
Figure 17. Global Peptide Based Infection Therapeutics Revenue Market Share by Type (2016-2021)
Figure 18. Global Peptide Based Infection Therapeutics Revenue Market Share by Type (2022-2027)
Figure 19. North America Peptide Based Infection Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Peptide Based Infection Therapeutics Market Share by Type (2016-2027)
Figure 21. North America Peptide Based Infection Therapeutics Market Share by Application (2016-2027)
Figure 22. North America Peptide Based Infection Therapeutics Market Share by Country (2016-2027)
Figure 23. United States Peptide Based Infection Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Peptide Based Infection Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Peptide Based Infection Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Peptide Based Infection Therapeutics Market Share by Type (2016-2027)
Figure 27. Europe Peptide Based Infection Therapeutics Market Share by Application (2016-2027)
Figure 28. Europe Peptide Based Infection Therapeutics Market Share by Country (2016-2027)
Figure 29. Germany Peptide Based Infection Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Peptide Based Infection Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Peptide Based Infection Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Peptide Based Infection Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Peptide Based Infection Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Peptide Based Infection Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Peptide Based Infection Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Peptide Based Infection Therapeutics Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Peptide Based Infection Therapeutics Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Peptide Based Infection Therapeutics Market Share by Region (2016-2027)
Figure 39. China Peptide Based Infection Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Peptide Based Infection Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Peptide Based Infection Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Peptide Based Infection Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Peptide Based Infection Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Peptide Based Infection Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Peptide Based Infection Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Peptide Based Infection Therapeutics Market Share by Type (2016-2027)
Figure 47. Latin America Peptide Based Infection Therapeutics Market Share by Application (2016-2027)
Figure 48. Latin America Peptide Based Infection Therapeutics Market Share by Country (2016-2027)
Figure 49. Mexico Peptide Based Infection Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Peptide Based Infection Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Peptide Based Infection Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Peptide Based Infection Therapeutics Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Peptide Based Infection Therapeutics Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Peptide Based Infection Therapeutics Market Share by Country (2016-2027)
Figure 55. Turkey Peptide Based Infection Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Peptide Based Infection Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Peptide Based Infection Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Gilead Sciences Revenue Growth Rate in Peptide Based Infection Therapeutics Business (2016-2021)
Figure 59. Johnson & Johnson (Janssen) Revenue Growth Rate in Peptide Based Infection Therapeutics Business (2016-2021)
Figure 60. Vertex Pharmaceuticals Revenue Growth Rate in Peptide Based Infection Therapeutics Business (2016-2021)
Figure 61. Mitsubishi Tanabe Pharma Revenue Growth Rate in Peptide Based Infection Therapeutics Business (2016-2021)
Figure 62. Medivir Revenue Growth Rate in Peptide Based Infection Therapeutics Business (2016-2021)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed


【掲載企業】

Gilead Sciences、Johnson & Johnson (Janssen)、Vertex Pharmaceuticals、Mitsubishi Tanabe Pharma、Medivir

★調査レポート[世界のペプチドベース感染症治療薬市場規模・現状・予測2021-2027] (コード:QY21APR4500)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のペプチドベース感染症治療薬市場規模・現状・予測2021-2027]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆